$249.89
0.35% today
NYSE, Feb 28, 04:46 pm CET
ISIN
US03073E1055
Symbol
COR

Cencora Stock price

$249.01
-5.88 2.31% 1M
+15.51 6.64% 6M
+24.33 10.83% YTD
+12.50 5.29% 1Y
+106.48 74.71% 3Y
+162.42 187.57% 5Y
+146.25 142.32% 10Y
NYSE, Closing price Thu, Feb 27 2025
-1.64 0.65%
ISIN
US03073E1055
Symbol
COR
Sector

Key metrics

Market capitalization $48.29b
Enterprise Value $53.24b
P/E (TTM) P/E ratio 35.43
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.18
P/S ratio (TTM) P/S ratio 0.16
P/B ratio (TTM) P/B ratio 213.04
Dividend yield 0.82%
Last dividend (FY24) $2.04
Revenue growth (TTM) Revenue growth 11.64%
Revenue (TTM) Revenue $303.19b
EBIT (operating result TTM) EBIT $3.04b
Free Cash Flow (TTM) Free Cash Flow $-638.10m
Cash position $3.33b
EPS (TTM) EPS $7.03
P/E forward 19.19
P/S forward 0.15
EV/Sales forward 0.17
Short interest 7.98%
Show more

Is Cencora a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Cencora Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Cencora forecast:

11x Buy
65%
6x Hold
35%

Analyst Opinions

17 Analysts have issued a Cencora forecast:

Buy
65%
Hold
35%

Financial data from Cencora

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
303,193 303,193
12% 12%
100%
- Direct Costs 294,422 294,422
12% 12%
97%
8,771 8,771
10% 10%
3%
- Selling and Administrative Expenses 4,620 4,620
6% 6%
2%
- Research and Development Expense - -
-
-
4,151 4,151
14% 14%
1%
- Depreciation and Amortization 1,115 1,115
4% 4%
0%
EBIT (Operating Income) EBIT 3,037 3,037
18% 18%
1%
Net Profit 1,396 1,396
25% 25%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Cencora directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cencora Stock News

Positive
Seeking Alpha
2 days ago
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. The company has a strong economic moat, low leverage, BBB+ credit rating, and an active share repurchase program, enhancing shareholder returns. Strategic acquisitions like Retina Consultants of America position Cencora for long-term success, with management g...

Company Profile

AmerisourceBergen Corp. engages provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.

Head office United States
CEO Robert Mauch
Employees 46,000
Founded 1947
Website www.cencora.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today